Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis

Vikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampon, Hsin-An Hou, Grzegorz Helbig, Argiris S. Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, David M Ross

Blood (2023) 142 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2023-173942

Published: 2023

Journal Articles

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Polona Novak, Vaneuza Funke, Vanderson Rocha, Nelson Hamerschlak, Thomas Schroeder, Christina Rautenberg, Linette Bosques, Raffaella Greco, Artur Schneider, Grzegorz Helbig, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2023-191300

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil Compared to Anti-Thymocyte Globulin tacrolimus or Cyclosporine a and Methotrexate Combinations As Graft- versus -Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2023-174821

Published: 2023

Journal Articles

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2023-180686

Published: 2023

Journal Articles

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Blood (2023) 142 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2023-189713

Published: 2023

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Blood (2022) 140 (Supplement 1): 10547–10549.

https://doi.org/10.1182/blood-2022-162546

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Blood (2021) 138 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2021-151000

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143003

Published: 2020

Journal Articles

BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society

Riccardo Saccardi, MD, Manuela Badoglio, Joachim Burman, Grzegorz Helbig, Majid A. Kazmi, FRCP, Giovanni Mancardi, Stephan Mielke, MD, John Moore, MDFRACP,FRCPA, Paolo Muraro, Jaime Sanz, MD PhD, Basil Sharrack, Marek Smilowski, Maria Pia Sormani, John A Snowden, MD PhD

Blood (2019) 134 (Supplement_1): 3313.

https://doi.org/10.1182/blood-2019-125233

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT

Noga Shem-Tov, MD, Christophe Peczynski, Myriam Labopin, MD, Maija Itälä-Remes, MD PhD, Didier Blaise, Hélène Labussière-Wallet, Gérard Socié, MDPhD, Nicolaus Kröger, MD, Per Ljungman, MD PhD, Boris Afanasyev, Patrice Chevallier, MD, Johanna Tischer, Grzegorz Helbig, Pavel Jindra, MD PhD, Sebastian Giebel, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2018-99-111604

Published: 2018

Journal Articles

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

Kateřina Kuželová, PhD, Christoph Röllig, MD, Zdenek Racil, MD, Juliane S. Stickel, MD, Barbora Brodská, PhD, Johannes Schetelig, MD MSc, Christian Thiede, MD, Gerhard Ehninger, MD, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, Prof, Jiri Mayer, Petr Cetkovsky, MD MBA, PhD

Blood (2016) 128 (22): 5230.

https://doi.org/10.1182/blood.V128.22.5230.5230

Published: 2016

Journal Articles

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Blood (2016) 128 (22): 213.

https://doi.org/10.1182/blood.V128.22.213.213

Published: 2016

Journal Articles

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Katerina Kuzelova, PhD, Barbora Brodská, PhD, Jana Marková, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2015) 126 (23): 2572.

https://doi.org/10.1182/blood.V126.23.2572.2572

Published: 2015

NARROW

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Meter: A Multi-Country, Real-World Chart Review Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients with Myelofibrosis

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group

BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society

Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only